- Psyched Wellness Ltd. (PSYC) collects preliminary data from studies on the neuroprotective properties of the mushroom extract, AME-1
- Preliminary findings continue to demonstrate the anti-inflammatory properties in AME-1
- It also demonstrates also having a neuroprotective effect at the cellular level
- The study tested the extract on brain and spinal cells
- The positive findings will be used to aid the commercialization of AME-1 this spring
- Psyched Wellness Ltd. (PSYC) is unchanged trading at $0.15 per share as of 11:31 a.m. ET
Psyched Wellness (PSYC) has shared preliminary data from studies on the neuroprotective properties of the AME-1 extract.
The study is the first of a series to explore the neuroprotective properties of AME-1 and examine if the anti-inflammatory properties have any potential neuroprotective activities.
Jeffrey Stevens, CEO of Psyched, commented,
“As we focus on commercialization of our AME-1 tinctures in the United States this spring, these studies provide evidence for the potential of many additional future uses of AME-1 to ensure we can offer consumers options for their health and wellness needs.”
Preliminary findings continue to demonstrate the anti-inflammatory properties of AME-1 and indicate that it does not cause cell damage while also having a neuroprotective effect at the cellular level.
The first part focused on the ability of AME-1 to protect neuronal brain and spinal cord cells from inflammatory mediator-induced cell damage and monitored the cell surface expression of apoptotic markers using annexin V and propidium iodide.
The results of the study showed that AME-1 did have a neuroprotective effect on brain and spinal cells that were treated with a pro-inflammatory mediator, which was determined to be concentration dependence.
The second part was to determine whether AME-1 has any direct inhibitory effects on one of the pro-apoptotic cellular pathways, such as the induction of caspase-3.
Caspase-3 has been published to be important in the cell death process and is responsible for the breaking of key proteins in the cell nucleus.
AME-1 did not increase caspase-3 activity and did not induce any cell death effects. However, there was no inhibition of this pathway which can be explained by the fact AME-1 may influence another cell-damaging pathway not investigated yet.
Psyched Wellness Ltd. (PSYC) is unchanged trading at $0.15 per share as of 11:31 a.m. ET.
